Defence Therapeutics Announces Warrant Terms Amendment

Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("**Defence**" or the "**Company**"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "**Warrants**") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and the exercise price will be repriced at $0.75 per Common Share, as follows:

No. of Warrants	Original Expiry Date of Warrants	New Expiry Date of Warrants	Original Exercise Price of Warrants	New Exercise Price of Warrants
775,000	October 30, 2026	October 30, 2027	$1.00	$0.75
25,000	November 29, 2026	November 29, 2027	$1.00	$0.75

None of the Warrants have been exercised as of the date hereof. All other terms of the Warrants will remain unchanged. In accordance with the requirements of the Canadian Securities Exchange, the terms of any warrants issued as compensation warrants or as finder warrants are not eligible for amendment. The amendments are subject to the final approval of the CSE.

About Defence Therapeutics:

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.

For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the

Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

defence
THERAPEUTICS

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289329